Investigation of novel compounds via in silico approaches of EGFR inhibitors as anticancer agents
Özet
Before the experimental studies of a compound to be synthesized from in vitro to in vivo, it is possible to save both time and money with in silico approaches only with Computer Aided Drug Design (CADD) methods. In other words, compounds that can be new drug candidates can be suggested by drug design using computational drug discovery strategies. In this study, all molecules in the ChEMBL Database were virtual screened based on drugs with inhibitory properties on the Epidermal Growth Factor Receptor (EGFR), one of the receptor tyrosine kinases, which is effective in cancer cells. During this High-Throughput Screening (HTS), the number of compounds was minimized according to the parameters of the reference drugs, physicochemical properties such as logP, M.W., HBA, HDB, RosLip. As a result of in silico approaches and molecular docking analysis, ten compounds with the highest docking scores were determined and a model compound that could be a new drug candidate was proposed. © 2022 Indian Chemical Society
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Türkmenoğlu, Burçin | |
| dc.date.accessioned | 2026-10-18T20:27:44.271553085Z | |
| dc.date.available | 2026-10-18T20:27:44.271553085Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Before the experimental studies of a compound to be synthesized from in vitro to in vivo, it is possible to save both time and money with in silico approaches only with Computer Aided Drug Design (CADD) methods. In other words, compounds that can be new drug candidates can be suggested by drug design using computational drug discovery strategies. In this study, all molecules in the ChEMBL Database were virtual screened based on drugs with inhibitory properties on the Epidermal Growth Factor Receptor (EGFR), one of the receptor tyrosine kinases, which is effective in cancer cells. During this High-Throughput Screening (HTS), the number of compounds was minimized according to the parameters of the reference drugs, physicochemical properties such as logP, M.W., HBA, HDB, RosLip. As a result of in silico approaches and molecular docking analysis, ten compounds with the highest docking scores were determined and a model compound that could be a new drug candidate was proposed. © 2022 Indian Chemical Society | |
| dc.description.sponsorship | Author would like to thank Erzincan Binali Yıldırım University, Basic Sciences Application and Research Center (EBYU-EUTAM) for the Schrödinger Maestro 2021–2 program. | |
| dc.identifier.doi | 10.1016/j.jics.2022.100601 | |
| dc.identifier.issn | 0019-4522 | |
| dc.identifier.issue | 8 | |
| dc.identifier.scopus | 2-s2.0-85133459345 | |
| dc.identifier.startpage | 100601 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12878 | |
| dc.identifier.volume | 99 | |
| dc.identifier.wos | WOS:000827216400002 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | Journal of the Indian Chemical Society | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | CADD | |
| dc.subject | EGFR | |
| dc.subject | Erlotinib | |
| dc.subject | Molecular docking | |
| dc.subject | afatinib | |
| dc.subject | amino acid | |
| dc.subject | antineoplastic agent | |
| dc.subject | epidermal growth factor receptor | |
| dc.subject | epidermal growth factor receptor kinase inhibitor | |
| dc.subject | gefitinib | |
| dc.subject | osimertinib | |
| dc.subject | tyrosine kinase receptor | |
| dc.subject | Article | |
| dc.subject | binding site | |
| dc.subject | cancer cell | |
| dc.subject | computer model | |
| dc.subject | controlled study | |
| dc.subject | crystal structure | |
| dc.subject | data base | |
| dc.subject | drug design | |
| dc.subject | drug efficacy | |
| dc.subject | high throughput screening | |
| dc.subject | hydrogen bond | |
| dc.subject | non small cell lung cancer | |
| dc.subject | physical chemistry | |
| dc.subject | protein database | |
| dc.title | Investigation of novel compounds via in silico approaches of EGFR inhibitors as anticancer agents | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 26 | |
| rdl.citation.wos | 27 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
